203 Pb-VMT-α-NET Scintigraphy of a Patient With Neuroendocrine Tumor.
Journal
Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109
Informations de publication
Date de publication:
01 Jan 2023
01 Jan 2023
Historique:
pubmed:
19
10
2022
medline:
22
12
2022
entrez:
18
10
2022
Statut:
ppublish
Résumé
In an end-stage midgut neuroendocrine tumor patient with carcinoid heart disease, right ventricular dysfunction, mildly reduced renal function, and refractory to 6 cycles of 177 Lu-HA-DOTATATE therapy, planar, and 22 hours SPECT/CT images were acquired after injection of 224 MBq of 203 Pb-VMT-α-NET to assess the feasibility of performing 212 Pb-VMT-α-NET therapy. A comparison of the 1.5 and 22 hours SPECT/CT images with 68 Ga-HA-DOTATATE PET/CT showed high uptake of 203 Pb-VMT-α-NET in liver metastases matching with the results of the PET/CT investigation.
Identifiants
pubmed: 36257061
doi: 10.1097/RLU.0000000000004464
pii: 00003072-202301000-00009
pmc: PMC9762701
doi:
Substances chimiques
Lead
2P299V784P
copper dotatate CU-64
0
Octreotide
RWM8CCW8GP
Organometallic Compounds
0
Radiopharmaceuticals
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
54-55Subventions
Organisme : NCI NIH HHS
ID : P30 CA086862
Pays : United States
Informations de copyright
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
Conflicts of interest and sources of funding: The author M.K.S. is inventor of the peptide VMT-α-NET and CSO (Chief Science Officer) of Viewpoint Molecular Targeting, Inc. There is no conflict of interest with respect to the other authors. The radiopharmaceutical 203 Pb-VMT-α-NET was manufactured under cGMP conditions and applied in accordance with the German National Law (§13 [2b] AMG).
Références
Li M, Zhang X, Quinn TP, et al. Automated cassette-based production of high specific activity [ 203/212 Pb]peptide-based theranostic radiopharmaceuticals for image-guided radionuclide therapy for cancer. Appl Radiat Isot . 2017;127:52–60. Erratum in: Appl Radiat Isot . 2020;156:108733.
Li M, Sagastume EA, Lee D, et al. 203/212 Pb theranostic radiopharmaceuticals for image-guided radionuclide therapy for cancer. Curr Med Chem . 2020;27:7003–7031.
Zaid NRR, Kletting P, Beer AJ, et al. Mathematical modeling of in vivo alpha particle generators and chelator stability. Cancer Biother Radiopharm . 2021. doi:10.1089/cbr.2020.4112. Epub ahead of print.
doi: 10.1089/cbr.2020.4112
Zaid NRR, Kletting P, Winter G, et al. A physiologically based pharmacokinetic model for in vivo alpha particle generators targeting neuroendocrine tumors in mice. Pharmaceutics . 2021;13:2132.
Li M, Liu D, Lee D, et al. Targeted alpha-particle radiotherapy and immune checkpoint inhibitors induces cooperative inhibition on tumor growth of malignant melanoma. Cancers (Basel) . 2021;13:3676.
Dos Santos JC, Schäfer M, Bauder-Wüst U, et al. Development and dosimetry of 203 Pb/ 212 Pb-labelled PSMA ligands: bringing “the lead” into PSMA-targeted alpha therapy? Eur J Nucl Med Mol Imaging . 2019;46:1081–1091.
Schottelius M, Šimeček J, Hoffmann F, et al. Twins in spirit—episode I: comparative preclinical evaluation of [(68)Ga]DOTATATE and [(68)Ga]HA-DOTATATE. EJNMMI Res . 2015;5:22.
Schottelius M, Wester HJ, Reubi JC, et al. Improvement of pharmacokinetics of radioiodinated Tyr(3)-octreotide by conjugation with carbohydrates. Bioconjug Chem . 2002;13:1021–1030.